搜索
 > 【TRAIL R2】

TRAIL R2信息

英文名称:Tumor necrosis factor receptor superfamily member 10B
中文名称:肿瘤坏死因子受体超家族成员10B
靶点别称:Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-In
上市药物数量:0
临床药物数量:10
最高研发阶段:临床三期

TRAIL R2 分子别名

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

TRAIL R2 分子背景

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2 前沿进展

TRAIL R2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) 临床二期 Shenzhen Binder Biotechnology Co Ltd 肝癌, 食道癌, 胃癌, 胶质瘤, 肝细胞癌 详情
JCT-205 JCT-205 临床一期 Inhibrx 腺癌 详情
Eftozanermin alfa APG-350; APG-880; ABBV-621; PR-1625011 临床一期 艾伯维 血液肿瘤, 多发性骨髓瘤 详情
GEN-1029 iDD-004; GEN-1029; Hx-DR5-01; Hx-DR5-05 临床二期 Idd Biotech 胃癌, 转移性上皮癌, 肾细胞癌, 三阴性乳腺肿瘤, 胰腺癌, 结直肠癌, 非小细胞肺癌 详情
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) 临床三期 深圳未名新鹏生物医药有限公司 肿瘤 详情
Conatumumab AMG-655 临床二期 安进 卵巢癌, 实体瘤, 类癌瘤, 直肠癌, 卵巢上皮癌, 结肠癌, 胰腺癌, 肉瘤, 腹膜癌, 结直肠癌, 输卵管癌, 淋巴瘤, 非小细胞肺癌, 转移癌 详情
Circularly permuted TRAIL (Beijing Sunbio Biotech) 临床三期 北京沙东生物技术有限公司 多发性骨髓瘤 详情
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) CTB-006 临床一期 北京同为时代生物技术有限公司, 深圳龙瑞药业有限公司 实体瘤 详情
Dulanermin (Shanghai GeBaiDe) 临床三期 上海歌佰德生物技术有限公司 非小细胞肺癌 详情
BI-905711 BI-905711 临床一期 Boehringer Ingelheim Gmbh 胰腺癌, 胆管上皮癌, 胃肠道癌症 详情
Oba-01 Oba-01; Oba01 临床一期 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定